IMMU Share Price

Open 8.70 Change Price %
High 9.04 1 Day 0.12 1.39
Low 8.52 1 Week 1.25 16.71
Close 8.73 1 Month 1.15 15.17
Volume 3056277 1 Year 6.23 249.20
52 Week High 9.04
52 Week Low 1.95
IMMU Important Levels
Resistance 2 9.21
Resistance 1 9.01
Pivot 8.76
Support 1 8.45
Support 2 8.25
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.24 -11.11%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
GCFB 0.95 58.33%
FALC 0.38 52.00%
LOCM 0.09 50.00%
ENOC 7.65 41.67%
TROV 1.30 36.84%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AMRS 3.29 21.40%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

Immunomedics, Inc. (NASDAQ: IMMU)

IMMU Technical Analysis 5
As on 22nd Jun 2017 IMMU Share Price closed @ 8.73 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.46 & Strong Buy for SHORT-TERM with Stoploss of 6.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
IMMU Target for June
1st Target up-side 9.05
2nd Target up-side 10.1
3rd Target up-side 11.15
1st Target down-side 6.05
2nd Target down-side 5
3rd Target down-side 3.95
IMMU Other Details
Segment EQ
Market Capital 245243856.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.immunomedics.com
IMMU Address
IMMU
300 The American Road
Morris Plains, NJ 07950
United States
Phone: 973-605-8200
Fax: 973-605-8282
IMMU Latest News
Interactive Technical Analysis Chart Immunomedics, Inc. ( IMMU NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Immunomedics, Inc.
IMMU Business Profile
Immunomedics, Inc. is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow the Company to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. The Company has also tested antibody combinations as a possibly improved method of cancer therapy. The Company has licensed its product candidate, epratuzumab, to UCB S.A. (UCB), for the treatment of all non-cancer indications worldwide. Epratuzumab's advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE (lupus)), in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL).